Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery.

作者: Michael Weiss , Christine Giessler , Wonku Kang

DOI: 10.1097/01.CAD.0000185186.03099.31

关键词:

摘要: It has been hypothesized that coronary vasoconstriction is involved in the cardiotoxic action of anthracyclines. The purpose this study was to determine whether an increase resistance induced by idarubicin (IDA) or its primary circulating metabolite idarubicinol (IDOL) correlated with a decrease vascular sensitivity vasoconstrictor agonists. Coronary studied single-pass perfused rat hearts after 10-min infusion 0.5 mg IDA IDOL. In endothelium-intact thoracic aorta and mesentery we measured inhibition phenylephrine (PE)- KCl-induced contraction presence IDOL, respectively. evoked IDOL (121%) exceeded (75%). (10-100 micromol/l) concentration-dependently diminished PE KCl due reduction maximal contractile response (Emax), i.e. antagonism PE- non-competitive, indicating post-receptor cellular mechanism. These reductions efficacy elicited were significantly larger than those corresponding doses IDA. characterized IC50 estimates 44.3 30.7 mumol/l, With 10-fold lower IC50, inhibited reactivity small mesenteric arteries noradrenaline higher potency. correlation between responsiveness may suggest these anthracyclines act through common

参考文章(23)
Wonku Kang, Michael Weiss, Influence of P-Glycoprotein Modulators on Cardiac Uptake, Metabolism, and Effects of Idarubicin Pharmaceutical Research. ,vol. 18, pp. 1535- 1541 ,(2001) , 10.1023/A:1013022212738
Marie Joyeux, Diane Godin-Ribuot, Patrice Faure, Pierre Demenge, Christophe Ribuot, Heat stress protects against electrophysiological damages induced by acute doxorubicin exposure in isolated rat hearts. Cardiovascular Drugs and Therapy. ,vol. 15, pp. 219- 224 ,(2001) , 10.1023/A:1011960105874
Frank Kroschinsky, Eberhard Schleyer, Ulf Renner, Claudia Schimming, Christoph Schimmelpfennig, Martin Bornhäuser, Thomas Illmer, Lorenz Trümper, Gerhard Ehninger, Markus Schaich, Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study. Cancer Chemotherapy and Pharmacology. ,vol. 53, pp. 61- 67 ,(2004) , 10.1007/S00280-003-0700-2
Raymond B. Weiss, The anthracyclines: will we ever find a better doxorubicin? Seminars in Oncology. ,vol. 19, pp. 670- 686 ,(1992) , 10.5555/URI:PII:009377549290036Z
Francisco Pérez-Vizcaı́no, Manuel Ibarra, Angel L Cogolludo, Juan Duarte, Francisco Zaragozá-Arnáez, Laura Moreno, Gustavo López-López, Juan Tamargo, None, Endothelium-Independent Vasodilator Effects of the Flavonoid Quercetin and Its Methylated Metabolites in Rat Conductance and Resistance Arteries Journal of Pharmacology and Experimental Therapeutics. ,vol. 302, pp. 66- 72 ,(2002) , 10.1124/JPET.302.1.66
Wonku Kang, Michael Weiss, Modeling the Metabolism of Idarubicin to Idarubicinol in Rat Heart: Effect of Rutin and Phenobarbital Drug Metabolism and Disposition. ,vol. 31, pp. 462- 468 ,(2003) , 10.1124/DMD.31.4.462
Jacques Robert, Clinical Pharmacokinetics of Idarubicin Clinical Pharmacokinectics. ,vol. 24, pp. 275- 288 ,(1993) , 10.2165/00003088-199324040-00002
Ichiro Wakabayashi, Kunihiro Sakamoto, Katsuhiko Hatake, Hiroko Tanaka, Aclarubicin inhibits phosphatidylinositol hydrolysis and contraction of rat aorta European Journal of Pharmacology. ,vol. 255, pp. 111- 115 ,(1994) , 10.1016/0014-2999(94)90088-4
Michael Weiss, Wonku Kang, P-Glycoprotein Inhibitors Enhance Saturable Uptake of Idarubicin in Rat Heart: Pharmacokinetic/Pharmacodynamic Modeling Journal of Pharmacology and Experimental Therapeutics. ,vol. 300, pp. 688- 694 ,(2002) , 10.1124/JPET.300.2.688